Merck wins Fosamax preemption case at SCOTUS

Merck & Co. notched a victory today as the U.S. Supreme Court vacated an appeals court decision and said several hundred Fosamax suits are barred by federal law and shouldn’t have been reinstated. Plaintiffs alleged Merck didn’t warn quickly enough that the osteoporosis drug could cause atypical femoral fractures—thighbone breaks that happen without impact.